arrow_back Back to App

Strengthening Antimicrobial Resistance Fight: New Strategies and Surveillance

This act aims to enhance the U.S. government's efforts in combating the growing problem of antibiotic resistance. It means improved monitoring, faster threat detection, and the development of new drugs, directly leading to more effective infection treatment and greater public health safety for citizens.
Key points
Strengthening inter-agency cooperation to more effectively combat antimicrobial resistance.
Increasing surveillance of antibiotic use and bacterial resistance, with public data availability, to better understand the problem.
Developing a network of laboratories for faster detection and response to new, resistant bacterial strains.
Supporting research into new drugs, diagnostics, and vaccines to ensure effective treatment methods in the future.
Promoting programs to prevent the spread of resistant bacteria in healthcare and community settings.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_9094
Sponsor: Rep. Bera, Ami [D-CA-7]
Process start date: 2022-09-30
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

STAAR Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_9094.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-09-30.

What are the main provisions?

Key points include:

  • Strengthening inter-agency cooperation to more effectively combat antimicrobial resistance.
  • Increasing surveillance of antibiotic use and bacterial resistance, with public data availability, to better understand the problem.
  • Developing a network of laboratories for faster detection and response to new, resistant bacterial strains.
  • Supporting research into new drugs, diagnostics, and vaccines to ensure effective treatment methods in the future.
  • Promoting programs to prevent the spread of resistant bacteria in healthcare and community settings.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Bera, Ami [D-CA-7].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health